-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, Kunyao Group Co.
, Ltd.
(hereinafter referred to as "Kunyao Group") and Beijing Wangshi Wisdom Co.
, Ltd.
(hereinafter referred to as "Wangshi Wisdom") once again signed a small molecule drug cooperation development agreement
.
The two parties will deepen the cooperation and development of small molecule drugs in the field of anti-tumor
In the first cooperation, the two parties conducted tentative development of a tumor target
.
The target market has a broad market prospect, but the existing patents are applied by MNC with earlier pipeline layout, and there is a problem that the rigid main skeleton patent is difficult to break through
In view of the fact that the results of the early cooperation have exceeded expectations, the two parties have decided to work together again for cooperative development, and bind the platforms and interests of the two parties in a more in-depth manner
.
Joining forces again this time, Wangshi Wisdom CEO Zhou Jielong said that Kunyao Group has a distinctive R&D layout, and continues to invest in the field of innovative drugs to strengthen its existing advantages
.
Thank you very much for the trust and support of Kunyao Group and the early investment in research and development resources.
Dr.
Lu Hejun, head of small molecule innovative drugs of Kunyao Group, said that Wangshi Wisdom has demonstrated strong R&D capabilities in the early cooperation, including the development concept of a large platform and a large system, precise definition of medical issues and creative use of data
.
We are very looking forward to developing deeper cooperation with Wangshi Wisdom, better integrating the advantages and resources of both parties, and creating a first-class R&D pipeline
Recently, Kunyao Group Co.
, Ltd.
(hereinafter referred to as "Kunyao Group") and Beijing Wangshi Wisdom Co.
, Ltd.
(hereinafter referred to as "Wangshi Wisdom") once again signed a small molecule drug cooperation development agreement
.
The two parties will deepen the cooperation and development of small molecule drugs in the field of anti-tumor
In the first cooperation, the two parties conducted tentative development of a tumor target
.
The target market has a broad market prospect, but the existing patents are applied by MNC with earlier pipeline layout, and there is a problem that the rigid main skeleton patent is difficult to break through
In view of the fact that the results of the early cooperation have exceeded expectations, the two parties have decided to work together again for cooperative development, and bind the platforms and interests of the two parties in a more in-depth manner
.
Joining forces again this time, Wangshi Wisdom CEO Zhou Jielong said that Kunyao Group has a distinctive R&D layout, and continues to invest in the field of innovative drugs to strengthen its existing advantages
.
Thank you very much for the trust and support of Kunyao Group and the early investment in research and development resources.
Dr.
Lu Hejun, head of small molecule innovative drugs of Kunyao Group, said that Wangshi Wisdom has demonstrated strong R&D capabilities in the early cooperation, including the development concept of a large platform and a large system, precise definition of medical issues and creative use of data
.
We are very looking forward to developing deeper cooperation with Wangshi Wisdom, better integrating the advantages and resources of both parties, and creating a first-class R&D pipeline
.
